PhaseBio Pharmaceuticals Inc. (PHAS) PT Lowered to $11 at Citi
Tweet
Share
E-mailGet Alerts PHAS Hot Sheet
Price: $0.07 --0%
Rating Summary:
2 Buy, 4 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 10 | Down: 16 | New: 19
Rating Summary:
2 Buy, 4 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 10 | Down: 16 | New: 19
Join SI Premium – FREE
Citi analyst Joel Beatty lowered the price target on PhaseBio Pharmaceuticals Inc. (NASDAQ: PHAS) to $11.00 (from $25.00) while maintaining a Buy rating.
You May Also Be Interested In
- Harley-Davidson (HOG) PT Raised to $33 at DA Davidson Amid Progress on Back to Bricks Strategy
- ERock Inc (EROC) PT Raised to $23 at Morgan Stanley
- Disc Medicine (IRON) PT Raised to $90 at Morgan Stanley
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
